CDK9-IN-22

• Description:

  CDK9-IN-22 is a potent CDK9 inhibitor with IC50s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity[1].

• UNSPSC:

  12352005

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk9-in-22.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CN(CCNC(C1=CC=C(C=C1)NC2=NC(C3=C(C=C(C=C3)F)OCC4=CC=CC=C4)=CC=N2)=O)C

• Molecular Formula:

  C28H28FN5O2

• Molecular Weight:

  485.55

• References & Citations:

  [1]Xu Z, et al. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors. Eur J Med Chem. 2022 Dec 15;244:114875.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK2; CDK9

• CAS Number:

  [2872677-61-5]